Braveheart Bio, Inc. (NASDAQ:BRVE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Braveheart Bio, Inc. (NASDAQ:BRVE) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $45.25.

BRVE has been the subject of several analyst reports. Cantor Fitzgerald began coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued an “overweight” rating and a $40.00 target price for the company. Zacks Research raised shares of Braveheart Bio to a “hold” rating in a research report on Tuesday, September 1st. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Stifel Nicolaus assumed coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $45.00 target price on the stock. Finally, TD Cowen assumed coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating on the stock.

Insider Buying and Selling at Braveheart Bio

In other Braveheart Bio news, major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of Braveheart Bio stock in a transaction on Friday, August 7th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $19,800,000.00. Following the purchase, the insider directly owned 10,232,420 shares of the company’s stock, valued at $184,183,560. This trade represents a 12.05% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc bought 1,940,000 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the purchase, the director directly owned 11,901,826 shares in the company, valued at approximately $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 8,751,942 shares of company stock valued at $157,534,956 in the last ninety days.

Braveheart Bio Price Performance

NASDAQ BRVE opened at $26.74 on Monday. Braveheart Bio has a 12 month low of $24.31 and a 12 month high of $32.00.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.